 Henry Galan
Concepts (517)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Growth Retardation | 50 | 2023 | 549 | 6.910 |
Why?
| | Ultrasonography, Prenatal | 37 | 2024 | 275 | 4.310 |
Why?
| | Placenta | 29 | 2022 | 716 | 2.810 |
Why?
| | Ultrasonography, Doppler | 19 | 2023 | 118 | 2.640 |
Why?
| | Pregnancy | 108 | 2024 | 6412 | 2.620 |
Why?
| | Umbilical Arteries | 12 | 2023 | 53 | 2.390 |
Why?
| | Gestational Age | 37 | 2024 | 875 | 1.840 |
Why?
| | Gynecology | 4 | 2022 | 174 | 1.510 |
Why?
| | Uterine Artery | 6 | 2020 | 78 | 1.500 |
Why?
| | Fetus | 24 | 2023 | 780 | 1.480 |
Why?
| | Sheep | 27 | 2017 | 840 | 1.410 |
Why?
| | Pregnancy Outcome | 11 | 2024 | 391 | 1.380 |
Why?
| | Meningomyelocele | 5 | 2022 | 56 | 1.280 |
Why?
| | Fetal Weight | 7 | 2022 | 55 | 1.200 |
Why?
| | Pregnancy, Twin | 4 | 2022 | 18 | 1.180 |
Why?
| | Obstetrics | 6 | 2022 | 162 | 1.080 |
Why?
| | Fetal Diseases | 7 | 2024 | 164 | 1.070 |
Why?
| | Fetofetal Transfusion | 4 | 2022 | 20 | 1.050 |
Why?
| | Infant, Newborn | 36 | 2024 | 5769 | 1.020 |
Why?
| | Infant, Small for Gestational Age | 7 | 2022 | 84 | 0.950 |
Why?
| | Fetal Development | 3 | 2021 | 287 | 0.950 |
Why?
| | Female | 113 | 2024 | 68650 | 0.940 |
Why?
| | Inositol | 5 | 2014 | 26 | 0.850 |
Why?
| | Delivery, Obstetric | 5 | 2021 | 136 | 0.820 |
Why?
| | Sorbitol | 4 | 2014 | 14 | 0.760 |
Why?
| | Comorbidity | 2 | 2024 | 1548 | 0.760 |
Why?
| | Nitric Oxide Synthase Type III | 6 | 2011 | 201 | 0.750 |
Why?
| | Umbilical Veins | 6 | 2009 | 61 | 0.710 |
Why?
| | Hydrocephalus | 4 | 2024 | 103 | 0.700 |
Why?
| | Pregnancy Complications | 7 | 2024 | 493 | 0.700 |
Why?
| | Infant, Newborn, Diseases | 1 | 2022 | 111 | 0.690 |
Why?
| | Cerclage, Cervical | 2 | 2022 | 6 | 0.690 |
Why?
| | Hernias, Diaphragmatic, Congenital | 4 | 2024 | 200 | 0.660 |
Why?
| | X-Linked Inhibitor of Apoptosis Protein | 2 | 2010 | 12 | 0.640 |
Why?
| | Uterine Cervical Incompetence | 1 | 2019 | 3 | 0.640 |
Why?
| | Altitude | 4 | 2013 | 462 | 0.620 |
Why?
| | Pregnancy, Animal | 4 | 2012 | 52 | 0.600 |
Why?
| | Pre-Eclampsia | 4 | 2015 | 187 | 0.590 |
Why?
| | Placental Insufficiency | 7 | 2017 | 112 | 0.590 |
Why?
| | Birth Weight | 9 | 2021 | 504 | 0.580 |
Why?
| | Amniotic Fluid | 8 | 2024 | 87 | 0.570 |
Why?
| | Humans | 93 | 2024 | 129527 | 0.560 |
Why?
| | Internship and Residency | 3 | 2022 | 1049 | 0.540 |
Why?
| | Atrioventricular Block | 1 | 2017 | 35 | 0.530 |
Why?
| | Bradycardia | 1 | 2017 | 53 | 0.530 |
Why?
| | Regional Blood Flow | 8 | 2011 | 464 | 0.530 |
Why?
| | Prenatal Diagnosis | 5 | 2024 | 195 | 0.520 |
Why?
| | Blood Flow Velocity | 7 | 2022 | 406 | 0.510 |
Why?
| | Laser Coagulation | 1 | 2016 | 57 | 0.500 |
Why?
| | Maternal-Fetal Exchange | 8 | 2021 | 162 | 0.490 |
Why?
| | Body Composition | 5 | 2022 | 649 | 0.490 |
Why?
| | Adipose Tissue | 3 | 2016 | 594 | 0.460 |
Why?
| | Uterus | 3 | 2011 | 207 | 0.450 |
Why?
| | Amino Acids | 4 | 2021 | 487 | 0.440 |
Why?
| | Premature Birth | 5 | 2024 | 317 | 0.440 |
Why?
| | Disease Models, Animal | 15 | 2021 | 4073 | 0.440 |
Why?
| | Fetal Therapies | 5 | 2024 | 35 | 0.430 |
Why?
| | Nitric Oxide Synthase | 3 | 2006 | 233 | 0.420 |
Why?
| | Nitric Oxide | 7 | 2011 | 897 | 0.420 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 3 | 2014 | 169 | 0.420 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 484 | 0.410 |
Why?
| | Puerperal Disorders | 2 | 2008 | 31 | 0.400 |
Why?
| | Laser-Doppler Flowmetry | 3 | 2005 | 33 | 0.390 |
Why?
| | Pulsatile Flow | 7 | 2011 | 60 | 0.390 |
Why?
| | NFATC Transcription Factors | 1 | 2012 | 86 | 0.370 |
Why?
| | Apoptosis | 5 | 2017 | 2488 | 0.360 |
Why?
| | Iron-Dextran Complex | 2 | 2003 | 7 | 0.360 |
Why?
| | Retrospective Studies | 18 | 2024 | 14532 | 0.360 |
Why?
| | Blood Pressure | 4 | 2017 | 1735 | 0.350 |
Why?
| | Organ Size | 11 | 2015 | 455 | 0.350 |
Why?
| | Biometry | 2 | 2008 | 69 | 0.340 |
Why?
| | Amniocentesis | 4 | 2019 | 22 | 0.330 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2009 | 38 | 0.330 |
Why?
| | Hemodynamics | 8 | 2009 | 1094 | 0.330 |
Why?
| | Gastroschisis | 2 | 2020 | 21 | 0.330 |
Why?
| | Lung | 13 | 2024 | 3928 | 0.320 |
Why?
| | Pregnancy Reduction, Multifetal | 2 | 2021 | 5 | 0.320 |
Why?
| | Caspase 3 | 1 | 2010 | 244 | 0.320 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2011 | 427 | 0.310 |
Why?
| | Fetal Blood | 4 | 2024 | 318 | 0.310 |
Why?
| | Polycythemia | 2 | 2021 | 20 | 0.310 |
Why?
| | Amino Acids, Essential | 1 | 2008 | 13 | 0.310 |
Why?
| | Animals | 41 | 2021 | 35334 | 0.300 |
Why?
| | Heart Rate | 2 | 2012 | 804 | 0.290 |
Why?
| | Iliac Vein | 1 | 2008 | 11 | 0.290 |
Why?
| | Nutritional Status | 1 | 2010 | 328 | 0.290 |
Why?
| | Twins, Monozygotic | 2 | 2021 | 209 | 0.290 |
Why?
| | Papio | 5 | 2021 | 91 | 0.280 |
Why?
| | Femoral Vein | 1 | 2008 | 32 | 0.280 |
Why?
| | Iliac Artery | 1 | 2008 | 55 | 0.280 |
Why?
| | Adult | 28 | 2024 | 35505 | 0.280 |
Why?
| | Dystocia | 1 | 2007 | 11 | 0.280 |
Why?
| | Protein Kinases | 1 | 2009 | 314 | 0.280 |
Why?
| | Pregnancy Trimester, Third | 5 | 2024 | 109 | 0.260 |
Why?
| | MicroRNAs | 2 | 2024 | 677 | 0.260 |
Why?
| | Polyhydramnios | 2 | 2023 | 17 | 0.250 |
Why?
| | Venous Thrombosis | 1 | 2008 | 176 | 0.250 |
Why?
| | Airway Obstruction | 2 | 2020 | 154 | 0.250 |
Why?
| | Transcription Factors | 2 | 2014 | 1642 | 0.250 |
Why?
| | Retroviridae | 2 | 2002 | 96 | 0.240 |
Why?
| | Trophoblasts | 5 | 2015 | 189 | 0.240 |
Why?
| | Fetoscopy | 3 | 2022 | 26 | 0.230 |
Why?
| | Fellowships and Scholarships | 2 | 2018 | 278 | 0.230 |
Why?
| | RNA, Messenger | 7 | 2012 | 2697 | 0.220 |
Why?
| | Bartter Syndrome | 1 | 2023 | 7 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 339 | 0.220 |
Why?
| | Prospective Studies | 9 | 2024 | 7150 | 0.210 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2004 | 78 | 0.210 |
Why?
| | Asphyxia | 1 | 2003 | 20 | 0.210 |
Why?
| | Hernia, Umbilical | 1 | 2023 | 16 | 0.210 |
Why?
| | Prenatal Care | 4 | 2022 | 277 | 0.210 |
Why?
| | Abortion, Spontaneous | 1 | 2023 | 100 | 0.200 |
Why?
| | Pregnancy Proteins | 2 | 2015 | 36 | 0.200 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2024 | 121 | 0.200 |
Why?
| | Fever | 5 | 2009 | 298 | 0.200 |
Why?
| | Models, Animal | 3 | 2012 | 375 | 0.200 |
Why?
| | Osmolar Concentration | 3 | 2014 | 167 | 0.200 |
Why?
| | Transduction, Genetic | 2 | 2002 | 124 | 0.200 |
Why?
| | Pulmonary Surfactants | 2 | 1993 | 106 | 0.190 |
Why?
| | Fetal Monitoring | 1 | 2002 | 15 | 0.190 |
Why?
| | Uterine Cervical Diseases | 1 | 2022 | 6 | 0.190 |
Why?
| | Hot Temperature | 3 | 2014 | 369 | 0.190 |
Why?
| | Blood Vessels | 2 | 2000 | 184 | 0.190 |
Why?
| | Blood Circulation | 1 | 2002 | 41 | 0.190 |
Why?
| | Meconium | 1 | 2001 | 7 | 0.190 |
Why?
| | Genetic Vectors | 2 | 2002 | 309 | 0.190 |
Why?
| | Meconium Aspiration Syndrome | 1 | 2001 | 11 | 0.190 |
Why?
| | Cervix Uteri | 1 | 2022 | 49 | 0.190 |
Why?
| | Aspirin | 2 | 2015 | 378 | 0.190 |
Why?
| | Diet, Protein-Restricted | 1 | 2021 | 11 | 0.190 |
Why?
| | Case-Control Studies | 6 | 2024 | 3383 | 0.180 |
Why?
| | Rheology | 1 | 2022 | 91 | 0.180 |
Why?
| | Infant | 8 | 2023 | 9005 | 0.180 |
Why?
| | Emergencies | 1 | 2022 | 156 | 0.180 |
Why?
| | Amino Acid Transport System L | 1 | 2021 | 19 | 0.180 |
Why?
| | Embryonic and Fetal Development | 5 | 2002 | 95 | 0.180 |
Why?
| | Nasopharynx | 1 | 2001 | 69 | 0.180 |
Why?
| | Amino Acid Transport System A | 1 | 2021 | 37 | 0.180 |
Why?
| | Biomarkers | 4 | 2024 | 3968 | 0.180 |
Why?
| | Sensitivity and Specificity | 6 | 2015 | 1842 | 0.180 |
Why?
| | Retrognathia | 1 | 2020 | 5 | 0.180 |
Why?
| | Fetal Death | 3 | 2023 | 55 | 0.170 |
Why?
| | Bupivacaine | 1 | 2020 | 31 | 0.170 |
Why?
| | Heart Diseases | 1 | 2004 | 349 | 0.170 |
Why?
| | Micrognathism | 1 | 2020 | 15 | 0.170 |
Why?
| | Arm | 2 | 2016 | 106 | 0.170 |
Why?
| | Twins, Dizygotic | 1 | 2021 | 181 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 245 | 0.170 |
Why?
| | Umbilical Cord | 5 | 2010 | 83 | 0.170 |
Why?
| | Anesthetics, Local | 1 | 2020 | 79 | 0.170 |
Why?
| | Myometrium | 2 | 2011 | 37 | 0.170 |
Why?
| | Respiration | 4 | 2006 | 193 | 0.170 |
Why?
| | Ductus Arteriosus | 3 | 2018 | 73 | 0.170 |
Why?
| | Risk Factors | 8 | 2021 | 9779 | 0.170 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 895 | 0.160 |
Why?
| | Goats | 1 | 1999 | 26 | 0.160 |
Why?
| | Respiratory Distress Syndrome, Newborn | 3 | 1999 | 103 | 0.160 |
Why?
| | Anemia | 1 | 2021 | 161 | 0.160 |
Why?
| | Leg | 2 | 2016 | 222 | 0.160 |
Why?
| | Obstetric Surgical Procedures | 1 | 2019 | 6 | 0.160 |
Why?
| | Pregnancy Trimester, Second | 3 | 2017 | 77 | 0.160 |
Why?
| | Reference Values | 4 | 2008 | 795 | 0.160 |
Why?
| | Maternal Health | 1 | 2019 | 45 | 0.150 |
Why?
| | Immunohistochemistry | 4 | 2010 | 1684 | 0.150 |
Why?
| | Time Factors | 8 | 2019 | 6530 | 0.150 |
Why?
| | Tocolytic Agents | 1 | 2018 | 16 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 285 | 0.150 |
Why?
| | Indomethacin | 1 | 2018 | 79 | 0.150 |
Why?
| | Pain, Postoperative | 1 | 2020 | 244 | 0.150 |
Why?
| | Colorado | 7 | 2020 | 4403 | 0.150 |
Why?
| | Maternal Exposure | 1 | 2020 | 177 | 0.150 |
Why?
| | Biological Transport | 3 | 2021 | 405 | 0.140 |
Why?
| | Hyaline Membrane Disease | 2 | 1997 | 20 | 0.140 |
Why?
| | Hysterotomy | 1 | 2017 | 9 | 0.140 |
Why?
| | Antibiotic Prophylaxis | 2 | 2011 | 102 | 0.140 |
Why?
| | Cesarean Section | 3 | 2024 | 183 | 0.140 |
Why?
| | Cardiomyopathies | 1 | 2021 | 339 | 0.140 |
Why?
| | Duodenal Obstruction | 1 | 2017 | 4 | 0.140 |
Why?
| | Esophageal Atresia | 1 | 2017 | 24 | 0.130 |
Why?
| | Heart Defects, Congenital | 1 | 2024 | 796 | 0.130 |
Why?
| | Paralysis | 1 | 1997 | 68 | 0.130 |
Why?
| | Body Mass Index | 3 | 2019 | 2269 | 0.130 |
Why?
| | Attitude | 1 | 2018 | 254 | 0.130 |
Why?
| | Magnetic Resonance Imaging | 5 | 2024 | 3392 | 0.130 |
Why?
| | Intracranial Embolism and Thrombosis | 1 | 1995 | 6 | 0.130 |
Why?
| | Protein S Deficiency | 1 | 1995 | 7 | 0.130 |
Why?
| | Caspases | 1 | 2017 | 245 | 0.130 |
Why?
| | Placental Circulation | 3 | 2012 | 65 | 0.130 |
Why?
| | Aldehyde Reductase | 2 | 2014 | 28 | 0.120 |
Why?
| | Lateral Ventricles | 1 | 2016 | 36 | 0.120 |
Why?
| | Curriculum | 1 | 2022 | 922 | 0.120 |
Why?
| | Blotting, Western | 4 | 2011 | 1199 | 0.120 |
Why?
| | Hypertension | 1 | 2005 | 1235 | 0.120 |
Why?
| | Symporters | 2 | 2014 | 56 | 0.120 |
Why?
| | Hypertension, Pulmonary | 3 | 2022 | 1891 | 0.120 |
Why?
| | Mannose | 2 | 2012 | 25 | 0.120 |
Why?
| | Coronary Circulation | 1 | 2015 | 138 | 0.120 |
Why?
| | Choriocarcinoma | 1 | 2014 | 9 | 0.120 |
Why?
| | Fetal Heart | 1 | 2015 | 55 | 0.120 |
Why?
| | Saline Solution, Hypertonic | 1 | 2014 | 40 | 0.110 |
Why?
| | Cohort Studies | 4 | 2020 | 5423 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 316 | 0.110 |
Why?
| | Regression Analysis | 3 | 2008 | 994 | 0.110 |
Why?
| | Sheep Diseases | 1 | 2014 | 7 | 0.110 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2014 | 13 | 0.110 |
Why?
| | Calcium | 2 | 2011 | 1208 | 0.110 |
Why?
| | Caloric Restriction | 1 | 2015 | 111 | 0.110 |
Why?
| | Down-Regulation | 3 | 2021 | 631 | 0.110 |
Why?
| | Pilot Projects | 3 | 2020 | 1594 | 0.110 |
Why?
| | Bronchogenic Cyst | 1 | 2013 | 6 | 0.110 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 308 | 0.110 |
Why?
| | Young Adult | 6 | 2021 | 12438 | 0.110 |
Why?
| | Ultrasonography | 2 | 2022 | 708 | 0.110 |
Why?
| | Uterine Neoplasms | 1 | 2014 | 100 | 0.110 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2010 | 819 | 0.110 |
Why?
| | Coronary Vessels | 1 | 2015 | 239 | 0.100 |
Why?
| | Body Weights and Measures | 1 | 2013 | 35 | 0.100 |
Why?
| | Umbilicus | 1 | 2013 | 17 | 0.100 |
Why?
| | Rabbits | 3 | 2003 | 769 | 0.100 |
Why?
| | Fatty Alcohols | 1 | 1992 | 5 | 0.100 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 919 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2724 | 0.100 |
Why?
| | Phosphorylcholine | 1 | 1992 | 18 | 0.100 |
Why?
| | Femur | 3 | 2008 | 243 | 0.100 |
Why?
| | Amnion | 1 | 1992 | 28 | 0.100 |
Why?
| | Lung Volume Measurements | 2 | 2023 | 44 | 0.100 |
Why?
| | Signal Transduction | 4 | 2011 | 4916 | 0.100 |
Why?
| | NADP | 1 | 2012 | 47 | 0.100 |
Why?
| | Calcium Signaling | 2 | 2011 | 251 | 0.090 |
Why?
| | Estradiol | 3 | 2000 | 492 | 0.090 |
Why?
| | Isotope Labeling | 1 | 2012 | 73 | 0.090 |
Why?
| | Animals, Newborn | 5 | 2000 | 827 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1510 | 0.090 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1636 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 61 | 0.090 |
Why?
| | Pregnancy Trimesters | 1 | 2010 | 16 | 0.090 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2010 | 14 | 0.090 |
Why?
| | Abdomen | 2 | 2003 | 119 | 0.090 |
Why?
| | Keratin-18 | 1 | 2010 | 10 | 0.090 |
Why?
| | Galectins | 1 | 2010 | 22 | 0.090 |
Why?
| | Probability | 2 | 2001 | 302 | 0.090 |
Why?
| | Chorionic Villi | 1 | 2010 | 22 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1015 | 0.090 |
Why?
| | Carbohydrate Metabolism | 1 | 2010 | 61 | 0.080 |
Why?
| | Calcium Channels | 1 | 2011 | 163 | 0.080 |
Why?
| | Oxygen | 4 | 2008 | 914 | 0.080 |
Why?
| | Infant, Premature | 2 | 2012 | 541 | 0.080 |
Why?
| | Carbohydrates | 1 | 2010 | 64 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2011 | 226 | 0.080 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2009 | 11 | 0.080 |
Why?
| | Term Birth | 1 | 2009 | 20 | 0.080 |
Why?
| | TRPC Cation Channels | 1 | 2009 | 14 | 0.080 |
Why?
| | Diglycerides | 1 | 2009 | 61 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2018 | 1219 | 0.080 |
Why?
| | High-Frequency Ventilation | 2 | 1999 | 45 | 0.080 |
Why?
| | Cordocentesis | 1 | 2008 | 1 | 0.080 |
Why?
| | Middle Cerebral Artery | 1 | 2009 | 43 | 0.080 |
Why?
| | Angiography | 1 | 2009 | 197 | 0.080 |
Why?
| | Hyperthermia, Induced | 1 | 2010 | 108 | 0.080 |
Why?
| | Endoplasmic Reticulum | 1 | 2011 | 261 | 0.080 |
Why?
| | Crown-Rump Length | 1 | 2008 | 3 | 0.070 |
Why?
| | Endothelin-1 | 2 | 2008 | 178 | 0.070 |
Why?
| | Placenta Diseases | 1 | 2008 | 15 | 0.070 |
Why?
| | Blood Gas Analysis | 1 | 2008 | 73 | 0.070 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 36 | 0.070 |
Why?
| | Birth Injuries | 1 | 2007 | 10 | 0.070 |
Why?
| | Polyethylene Glycols | 1 | 1992 | 611 | 0.070 |
Why?
| | Fluorocarbons | 2 | 1999 | 109 | 0.070 |
Why?
| | Foot | 1 | 2008 | 89 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 338 | 0.070 |
Why?
| | Shoulder | 1 | 2007 | 86 | 0.070 |
Why?
| | Pulmonary Circulation | 2 | 2000 | 428 | 0.070 |
Why?
| | Body Weight | 3 | 2006 | 941 | 0.070 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2009 | 393 | 0.070 |
Why?
| | Risk | 1 | 2009 | 857 | 0.060 |
Why?
| | Sheep, Domestic | 1 | 2006 | 34 | 0.060 |
Why?
| | Polymers | 1 | 2010 | 479 | 0.060 |
Why?
| | Glucose Transporter Type 4 | 1 | 2006 | 39 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2009 | 548 | 0.060 |
Why?
| | Imaging, Three-Dimensional | 1 | 2009 | 530 | 0.060 |
Why?
| | Glucose Transporter Type 1 | 1 | 2006 | 50 | 0.060 |
Why?
| | Obesity | 1 | 2019 | 2875 | 0.060 |
Why?
| | Fetal Hypoxia | 1 | 2006 | 54 | 0.060 |
Why?
| | Vasodilation | 2 | 2000 | 476 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2007 | 93 | 0.060 |
Why?
| | Echocardiography | 2 | 2021 | 635 | 0.060 |
Why?
| | Biophysics | 1 | 2006 | 66 | 0.060 |
Why?
| | Receptors, Growth Factor | 2 | 2002 | 55 | 0.060 |
Why?
| | Cerebral Aqueduct | 1 | 2024 | 4 | 0.060 |
Why?
| | Labor, Obstetric | 1 | 2004 | 59 | 0.060 |
Why?
| | Cells, Cultured | 4 | 2014 | 4087 | 0.050 |
Why?
| | Body Size | 1 | 2004 | 102 | 0.050 |
Why?
| | Self Report | 2 | 2018 | 800 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2003 | 39 | 0.050 |
Why?
| | Heat-Shock Proteins | 2 | 2014 | 137 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2003 | 527 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 832 | 0.050 |
Why?
| | Fetal Movement | 2 | 2006 | 6 | 0.050 |
Why?
| | Brain Diseases | 1 | 2004 | 134 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 107 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 2 | 2014 | 123 | 0.050 |
Why?
| | Morbidity | 1 | 2023 | 300 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2004 | 157 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2002 | 1031 | 0.050 |
Why?
| | beta-Galactosidase | 1 | 2002 | 77 | 0.050 |
Why?
| | Cerebral Palsy | 1 | 2004 | 100 | 0.050 |
Why?
| | Face | 1 | 2003 | 165 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 63 | 0.050 |
Why?
| | Apgar Score | 1 | 2001 | 16 | 0.050 |
Why?
| | Perineum | 1 | 2001 | 26 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 127 | 0.050 |
Why?
| | Bone and Bones | 1 | 2004 | 295 | 0.050 |
Why?
| | Constriction | 2 | 2018 | 46 | 0.050 |
Why?
| | Laparoscopy | 2 | 1997 | 446 | 0.050 |
Why?
| | Light Coagulation | 1 | 2021 | 8 | 0.050 |
Why?
| | Italy | 1 | 2001 | 98 | 0.050 |
Why?
| | Suction | 1 | 2001 | 32 | 0.050 |
Why?
| | Algorithms | 1 | 2009 | 1614 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2019 | 10232 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2023 | 308 | 0.040 |
Why?
| | Endpoint Determination | 1 | 2001 | 76 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 381 | 0.040 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2023 | 398 | 0.040 |
Why?
| | Myocardium | 1 | 2006 | 981 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2003 | 406 | 0.040 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1950 | 0.040 |
Why?
| | Gene Transfer Techniques | 1 | 2001 | 163 | 0.040 |
Why?
| | Drainage | 1 | 2021 | 164 | 0.040 |
Why?
| | Airway Management | 1 | 2020 | 46 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2003 | 663 | 0.040 |
Why?
| | Gastrostomy | 1 | 2021 | 108 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2020 | 131 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 483 | 0.040 |
Why?
| | Maternal Age | 1 | 2020 | 125 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2021 | 169 | 0.040 |
Why?
| | Parietal Bone | 1 | 1999 | 8 | 0.040 |
Why?
| | Diffusion | 1 | 1999 | 117 | 0.040 |
Why?
| | Perinatal Death | 1 | 2019 | 21 | 0.040 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2019 | 34 | 0.040 |
Why?
| | Pulmonary Artery | 3 | 2000 | 1075 | 0.040 |
Why?
| | Insulin | 2 | 2006 | 2313 | 0.040 |
Why?
| | Male | 6 | 2012 | 63586 | 0.040 |
Why?
| | Arteries | 1 | 2000 | 266 | 0.040 |
Why?
| | Anthropometry | 1 | 1999 | 203 | 0.040 |
Why?
| | Cigarette Smoking | 1 | 2020 | 91 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 818 | 0.040 |
Why?
| | Phosphorylation | 2 | 2014 | 1714 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 952 | 0.040 |
Why?
| | Tibia | 1 | 1999 | 168 | 0.040 |
Why?
| | Pancuronium | 1 | 1997 | 4 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 1999 | 245 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2019 | 186 | 0.040 |
Why?
| | Neuromuscular Depolarizing Agents | 1 | 1997 | 4 | 0.040 |
Why?
| | Survival Rate | 1 | 2022 | 1870 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4891 | 0.030 |
Why?
| | Respiration, Artificial | 2 | 1999 | 615 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 1997 | 35 | 0.030 |
Why?
| | Intestinal Atresia | 1 | 2017 | 14 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 1997 | 117 | 0.030 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1997 | 62 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 1998 | 422 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2018 | 2013 | 0.030 |
Why?
| | Pulmonary Edema | 1 | 1997 | 106 | 0.030 |
Why?
| | Capillary Permeability | 1 | 1997 | 140 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2017 | 70 | 0.030 |
Why?
| | Administration, Inhalation | 4 | 1999 | 673 | 0.030 |
Why?
| | Length of Stay | 1 | 2001 | 1132 | 0.030 |
Why?
| | United States | 3 | 2018 | 13865 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1368 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2004 | 5078 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 944 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 148 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Insufflation | 1 | 1995 | 12 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2015 | 78 | 0.030 |
Why?
| | Transport Vesicles | 1 | 2015 | 17 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 1997 | 277 | 0.030 |
Why?
| | Placenta Growth Factor | 1 | 2015 | 24 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2000 | 1286 | 0.030 |
Why?
| | Twins | 1 | 2017 | 247 | 0.030 |
Why?
| | Aorta | 1 | 1998 | 407 | 0.030 |
Why?
| | Saimiri | 1 | 1995 | 9 | 0.030 |
Why?
| | Uterine Prolapse | 1 | 1995 | 14 | 0.030 |
Why?
| | Carbon Dioxide | 2 | 1995 | 260 | 0.030 |
Why?
| | Neutrophils | 2 | 1999 | 1209 | 0.030 |
Why?
| | Genetic Therapy | 1 | 1997 | 286 | 0.030 |
Why?
| | Urethral Diseases | 1 | 1995 | 19 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 757 | 0.030 |
Why?
| | DNA Fragmentation | 1 | 2014 | 42 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 756 | 0.030 |
Why?
| | Thoracotomy | 1 | 2013 | 75 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 873 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2734 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1491 | 0.030 |
Why?
| | Pregnancy in Diabetics | 1 | 1995 | 118 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1091 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2014 | 181 | 0.020 |
Why?
| | Surveys and Questionnaires | 3 | 2018 | 5429 | 0.020 |
Why?
| | Registries | 1 | 2020 | 1902 | 0.020 |
Why?
| | Injections | 1 | 1992 | 171 | 0.020 |
Why?
| | Hydrogen | 1 | 2012 | 65 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 1983 | 0.020 |
Why?
| | Heart Rate, Fetal | 2 | 2006 | 21 | 0.020 |
Why?
| | Carbon Isotopes | 1 | 2012 | 127 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 1993 | 581 | 0.020 |
Why?
| | Drug Combinations | 1 | 1992 | 329 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 1997 | 577 | 0.020 |
Why?
| | Radiography | 1 | 1993 | 798 | 0.020 |
Why?
| | Anticoagulants | 1 | 1995 | 637 | 0.020 |
Why?
| | Myo-Inositol-1-Phosphate Synthase | 1 | 2010 | 2 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1873 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 150 | 0.020 |
Why?
| | Gene Silencing | 1 | 2011 | 189 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 183 | 0.020 |
Why?
| | TRPC6 Cation Channel | 1 | 2009 | 2 | 0.020 |
Why?
| | Fructose | 1 | 2010 | 105 | 0.020 |
Why?
| | Risk Assessment | 1 | 2019 | 3255 | 0.020 |
Why?
| | Intracellular Space | 1 | 2009 | 69 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2011 | 206 | 0.020 |
Why?
| | Efficiency | 1 | 2009 | 92 | 0.020 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 2008 | 7 | 0.020 |
Why?
| | Sodium | 1 | 2009 | 204 | 0.020 |
Why?
| | Pulmonary Gas Exchange | 2 | 1999 | 121 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2019 | 2475 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 20409 | 0.020 |
Why?
| | Head | 1 | 2008 | 96 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 590 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 347 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 30 | 0.020 |
Why?
| | Heating | 1 | 2006 | 20 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 282 | 0.020 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2006 | 59 | 0.020 |
Why?
| | Glycogen | 1 | 2006 | 55 | 0.020 |
Why?
| | Forecasting | 1 | 2008 | 360 | 0.020 |
Why?
| | Receptor, Insulin | 1 | 2006 | 99 | 0.020 |
Why?
| | Gene Expression | 1 | 2011 | 1461 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2011 | 739 | 0.020 |
Why?
| | Body Temperature | 1 | 2006 | 214 | 0.020 |
Why?
| | Liver | 2 | 2010 | 1836 | 0.010 |
Why?
| | Lactic Acid | 1 | 2006 | 304 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 776 | 0.010 |
Why?
| | Hospitals, University | 1 | 2004 | 179 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 353 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2006 | 333 | 0.010 |
Why?
| | Nuclease Protection Assays | 1 | 2003 | 4 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2003 | 27 | 0.010 |
Why?
| | Blotting, Northern | 1 | 2003 | 196 | 0.010 |
Why?
| | Drinking | 1 | 2003 | 40 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2004 | 203 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 443 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 84 | 0.010 |
Why?
| | Respiratory Mechanics | 1 | 2003 | 65 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2003 | 70 | 0.010 |
Why?
| | Placentation | 1 | 2002 | 43 | 0.010 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2002 | 23 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 78 | 0.010 |
Why?
| | Galactosides | 1 | 2001 | 4 | 0.010 |
Why?
| | Lac Operon | 1 | 2001 | 46 | 0.010 |
Why?
| | Macaca | 1 | 2001 | 54 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2544 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 145 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2001 | 159 | 0.010 |
Why?
| | Child | 2 | 2020 | 20932 | 0.010 |
Why?
| | Stomach | 1 | 2001 | 107 | 0.010 |
Why?
| | Morphogenesis | 1 | 2002 | 158 | 0.010 |
Why?
| | Transgenes | 1 | 2001 | 177 | 0.010 |
Why?
| | Glucose | 1 | 2006 | 996 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2002 | 173 | 0.010 |
Why?
| | Species Specificity | 1 | 2002 | 568 | 0.010 |
Why?
| | Ligation | 1 | 2000 | 86 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 75 | 0.010 |
Why?
| | Trachea | 1 | 2001 | 230 | 0.010 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 4 | 0.010 |
Why?
| | Esophagus | 1 | 2001 | 250 | 0.010 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2000 | 144 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2000 | 159 | 0.010 |
Why?
| | Indoles | 1 | 2001 | 387 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1995 | 3622 | 0.010 |
Why?
| | Receptor, Endothelin A | 1 | 1997 | 63 | 0.010 |
Why?
| | Blood Glucose | 1 | 2006 | 2071 | 0.010 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 171 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 324 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 2774 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 170 | 0.010 |
Why?
| | Acidosis, Respiratory | 1 | 1995 | 3 | 0.010 |
Why?
| | Catheterization, Swan-Ganz | 1 | 1995 | 8 | 0.010 |
Why?
| | Central Venous Pressure | 1 | 1995 | 14 | 0.010 |
Why?
| | Postoperative Period | 1 | 1997 | 329 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2002 | 1118 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 1997 | 256 | 0.010 |
Why?
| | Pulmonary Wedge Pressure | 1 | 1995 | 66 | 0.010 |
Why?
| | Prolapse | 1 | 1995 | 5 | 0.010 |
Why?
| | General Surgery | 1 | 1997 | 150 | 0.010 |
Why?
| | Tidal Volume | 1 | 1995 | 85 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1997 | 325 | 0.010 |
Why?
| | Vulva | 1 | 1995 | 24 | 0.010 |
Why?
| | Anesthesia, General | 1 | 1995 | 60 | 0.010 |
Why?
| | Cardiac Output | 1 | 1995 | 157 | 0.010 |
Why?
| | Safety | 1 | 1997 | 335 | 0.010 |
Why?
| | Pressure | 1 | 1995 | 239 | 0.010 |
Why?
| | Catheterization, Peripheral | 1 | 1995 | 105 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1995 | 369 | 0.010 |
Why?
| | Vagina | 1 | 1995 | 174 | 0.010 |
Why?
| | Oxazoles | 1 | 1971 | 30 | 0.010 |
Why?
| | Penicillins | 1 | 1971 | 57 | 0.010 |
Why?
| | Databases, Factual | 1 | 1997 | 1261 | 0.010 |
Why?
| | Chronic Disease | 1 | 1997 | 1722 | 0.010 |
Why?
| | Leukocytes | 1 | 1971 | 304 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 1971 | 376 | 0.000 |
Why?
| | Middle Aged | 1 | 2006 | 31087 | 0.000 |
Why?
| | Mice | 1 | 2001 | 16973 | 0.000 |
Why?
| | Kidney | 1 | 1971 | 1382 | 0.000 |
Why?
| | Dicloxacillin | 1 | 1971 | 1 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1971 | 172 | 0.000 |
Why?
| | Imidazoles | 1 | 1971 | 235 | 0.000 |
Why?
| | Administration, Oral | 1 | 1971 | 783 | 0.000 |
Why?
| | Child, Preschool | 1 | 1971 | 10499 | 0.000 |
Why?
|
|
Galan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|